Recursion Pharmaceuticals (RXRX) EBIAT (2020 - 2025)
Recursion Pharmaceuticals' EBIAT history spans 6 years, with the latest figure at -$108.1 million for Q4 2025.
- For Q4 2025, EBIAT rose 39.56% year-over-year to -$108.1 million; the TTM value through Dec 2025 reached -$644.8 million, down 39.06%, while the annual FY2025 figure was -$644.8 million, 39.06% down from the prior year.
- EBIAT reached -$108.1 million in Q4 2025 per RXRX's latest filing, up from -$162.3 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$30.7 million in Q1 2021 to a low of -$202.5 million in Q1 2025.
- Average EBIAT over 5 years is -$93.1 million, with a median of -$84.0 million recorded in 2023.
- Peak YoY movement for EBIAT: crashed 152.01% in 2021, then soared 39.56% in 2025.
- A 5-year view of EBIAT shows it stood at -$64.9 million in 2021, then rose by 11.46% to -$57.5 million in 2022, then tumbled by 61.75% to -$93.0 million in 2023, then tumbled by 92.38% to -$178.9 million in 2024, then soared by 39.56% to -$108.1 million in 2025.
- Per Business Quant, the three most recent readings for RXRX's EBIAT are -$108.1 million (Q4 2025), -$162.3 million (Q3 2025), and -$171.9 million (Q2 2025).